JUBLPHARMA — Jubilant Pharmova Share Price
0.000.00%
Last trade - 00:00- IN₹100.96bn
- IN₹126.58bn
- IN₹62.82bn
- 90
- 15
- 98
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.22 | ||
| PEG Ratio (f) | 0.39 | ||
| EPS Growth (f) | 131.45% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.87 | ||
| Price to Tang. Book | 5.19 | ||
| Price to Free Cashflow | 759.82 | ||
| Price to Sales | 1.52 | ||
| EV to EBITDA | 14.92 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 3.09% | ||
| Return on Equity | 0.7% | ||
| Operating Margin | 4.48% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 91,108.17 | 59,757.88 | 60,985.35 | 61,301.64 | 62,817.28 | 68,684 | 75,820 | -3.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +7 | -17.43 | -5.36 | -31.67 | -78.58 | +121.47 | +131.45 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Directors
- Hari Bhartia CCH (64)
- Shyam Bhartia NEC (68)
- Arun Sharma CFO (54)
- Arvind Chokhany CFO (48)
- Syed Kazmi CEX
- Gurpartap Sachdeva CEX
- Chandan Sengar CEX (51)
- Rajiv Shah CCO (50)
- Anant Pande EDR
- Rajesh Srivastava EDR (50)
- Arjun Bhartia NED (31)
- Priyavrat Bhartia NED (41)
- Pramod Yadav NED (54)
- Vivek Mehra IND
- Sushil Roongta IND (67)
- Arun Seth IND (66)
- Ashok Misra NID
- Sudha Pillai NID
- S. Sridhar NID
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 21st, 1978
- Public Since
- November 9th, 1994
- No. of Shareholders
- 97,935
- No. of Employees
- 1,034
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 158,350,737
- Address
- 1A, Sector 16A, NOIDA, 201301
- Web
- https://www.jubl.com/
- Phone
- +91 1204361000
- Contact
- Naresh Kapoor
- Auditors
- BSR & Co. LLP
Upcoming Events for JUBLPHARMA
Q1 2025 Jubilant Pharmova Ltd Earnings Release
Similar to JUBLPHARMA
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Jubilant Pharmova share price?
As of Today at 19:12 UTC, shares in Jubilant Pharmova are trading at IN₹637.60. This share price information is delayed by 15 minutes.
How has the Jubilant Pharmova share price performed this year?
Shares in Jubilant Pharmova last closed at IN₹637.60 and the price had moved by +109.74% over the past 365 days. In terms of relative price strength the Jubilant Pharmova share price has outperformed the S&P BSE 100 Index by +58.96% over the past year.
What are the analyst and broker recommendations for Jubilant Pharmova?
The overall consensus recommendation for Jubilant Pharmova is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Jubilant Pharmova dividend yield?
The Jubilant Pharmova dividend yield is 0.78% based on the trailing twelve month period.
Does Jubilant Pharmova pay a dividend?
Last year, Jubilant Pharmova paid a total dividend of IN₹5.00, and it currently has a trailing dividend yield of 0.78%. We do not have any data on when Jubilant Pharmova is to next pay dividends.
When does Jubilant Pharmova next pay dividends?
We do not have data on when Jubilant Pharmova is to next pay dividends. The historic dividend yield on Jubilant Pharmova shares is currently 0.78%.
How do I buy Jubilant Pharmova shares?
To buy shares in Jubilant Pharmova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Jubilant Pharmova?
As of the previous close price of IN₹637.60, shares in Jubilant Pharmova had a market capitalisation of IN₹100.96bn.
Where are Jubilant Pharmova shares listed?
Here are the trading details for Jubilant Pharmova:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: JUBLPHARMA
What kind of share is Jubilant Pharmova?
Based on an overall assessment of its quality, value and momentum Jubilant Pharmova is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Jubilant Pharmova share price forecast for 2024?
The analyst consensus target price for shares in Jubilant Pharmova is IN₹772.50. That is 21.16% above the last closing price of IN₹637.60.
Analysts covering Jubilant Pharmova currently have a consensus Earnings Per Share (EPS) forecast of IN₹12.40 for the next financial year.
What is the trend in the Jubilant Pharmova share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Jubilant Pharmova. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +31.24%.
As of the last closing price of IN₹637.60, shares in Jubilant Pharmova were trading +32.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Jubilant Pharmova PE Ratio?
The Jubilant Pharmova PE ratio based on its reported earnings over the past 12 months is 22.22. The shares last closed at IN₹637.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Jubilant Pharmova?
Jubilant Pharmova's management team is headed by:
- Hari Bhartia - CCH
- Shyam Bhartia - NEC
- Arun Sharma - CFO
- Arvind Chokhany - CFO
- Syed Kazmi - CEX
- Gurpartap Sachdeva - CEX
- Chandan Sengar - CEX
- Rajiv Shah - CCO
- Anant Pande - EDR
- Rajesh Srivastava - EDR
- Arjun Bhartia - NED
- Priyavrat Bhartia - NED
- Pramod Yadav - NED
- Vivek Mehra - IND
- Sushil Roongta - IND
- Arun Seth - IND
- Ashok Misra - NID
- Sudha Pillai - NID
- S. Sridhar - NID